312 related articles for article (PubMed ID: 27354579)
21. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
22. Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy.
Margolis N; Markovits E; Markel G
Adv Drug Deliv Rev; 2019 Feb; 141():104-124. PubMed ID: 31276707
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunology - development of novel anti-cancer therapies.
Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A
Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078
[TBL] [Abstract][Full Text] [Related]
25. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
26. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
27. The role of systemic therapies in the management of melanoma brain metastases.
Lyle M; Long GV
Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
[TBL] [Abstract][Full Text] [Related]
28. Current options and future directions in the systemic treatment of metastatic melanoma.
A Schindler K; Postow MA
J Community Support Oncol; 2014 Jan; 12(1):20-6. PubMed ID: 24971399
[TBL] [Abstract][Full Text] [Related]
29. Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2016 Jan; 53():125-34. PubMed ID: 26707829
[TBL] [Abstract][Full Text] [Related]
30. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
Christiansen SA; Khan S; Gibney GT
Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
[TBL] [Abstract][Full Text] [Related]
31. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Aris M; Barrio MM
Front Immunol; 2015; 6():46. PubMed ID: 25709607
[TBL] [Abstract][Full Text] [Related]
32. A Review of Current and Pipeline Drugs for Treatment of Melanoma.
Natarelli N; Aleman SJ; Mark IM; Tran JT; Kwak S; Botto E; Aflatooni S; Diaz MJ; Lipner SR
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399429
[TBL] [Abstract][Full Text] [Related]
33. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
35. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
36. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract][Full Text] [Related]
37. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
39. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Gibney GT; Atkins MB
Clin Adv Hematol Oncol; 2015 Jul; 13(7):451-8. PubMed ID: 26353041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]